99% Lyophilized Peptide Vial Pancragen 20mg Bioregulator Peptide Powder Pancragen Custom Peptides Powder Pancragen for Research Use

• Customization: Available
• CAS No.: 2381089-83-2
• Formula: N/a
• EINECS: 200-001-8
• Type: Synthesis Material Intermediates
• Appearance: Powder
• Quality: Refined
• Colour: White
• Content: Standard
• Usage: Laboratory Reagents
• Source: Dry Powder
• Habit Appellation: Fine Chemicals
• Application: Scientific Research
• Property: Protein and Peptide
• Specific Usage: Research Peptides
• Note: No Tfa Salt
• From: Authoried Regluar Workshop
• Raw Powder: 1g/Bottle
• Vials: 20mg
• Attention: Research Use Only
• Transport Package: Customized
• Specification: 1G/Bottle 2mg/5mg/10mg per vial
• Trademark: Hoconbio
• Origin: China
• Production Capacity: 50000kits Per Month

Product Description

Pancragen is a tetrapeptide composed of the amino acid sequence Lys-Glu-Asp-Trp (KEDW). It is a synthetic analog derived from a peptide originally isolated from bovine pancreatic cells and has been identified as a potential peptide bioregulator with implications for pancreatic function and age-associated metabolic processes. Aimed at supporting pancreatic function, pancragen can interact with histones and DNA, potentially improving glucose metabolism and insulin production. It may also aid in tissue repair within the pancreas

Product Name	Vilon
CAS NO.	45234-02-4
Other name	H-LYS-GLU-OH
Appearance	White freeze-dried powder
Purity	98% HPLC
Application	Research peptides
Shelf Life	24 Months
Storage	Store at a temperature of 2-8 degrees, protected from light.

Vilon Structure
Molecular Formula: CH1N3O5
Molecular Weight: 257.30 g/mol
PubChem CID: 7010502
CAS No: 45234-02-4
Alternative Names: Lysylglutamate, normophthal, Lyslglutamic acid

Vilon, composed of just two amino acids, stands as the shortest peptide acknowledged for its biological impact. Studies suggest its potent anti-aging properties and its significant role as an influential regulator of immune function. Furthermore, compelling evidence supports Vilon's capacity to modulate the vascular system and contribute to hemostasis. While it showcases a capacity to diminish the occurrence and progression of spontaneous tumors, its effectiveness as an adjunctive therapy for cancer treatment, rather than prevention, remains uncertain. Despite this, staunch supporters, notably including Dr. Vladimir Anisimov, advocate for Vilon as a valuable geroprotective agent.